Company Description
Lexaria Bioscience Corp. operates as a biotechnology company.
It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.
The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids.
Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods.
Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Country | United States |
IPO Date | n/a |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 5 |
CEO | Michael Shankman CPA |
Contact Details
Address: 740 McCurdy Road Kelowna, United States | |
Website | https://lexariabioscience.com |
Stock Details
Ticker Symbol | LEXXW |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001348362 |
CUSIP Number | 52886N117 |
ISIN Number | US52886N1173 |
Employer ID | 20-2000871 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Michael Shankman CPA | Chief Financial Officer |
Kristin Hamilton | Director of Operations |
Vanessa Carle | Head of Legal |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 05, 2024 | 424B3 | Filing |
Dec 03, 2024 | 4 | Filing |
Nov 27, 2024 | DEF 14A | Filing |
Nov 26, 2024 | S-3 | Filing |
Nov 26, 2024 | 10-K | Annual Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | PRE 14A | Filing |
Oct 18, 2024 | 8-K | Current Report |
Oct 16, 2024 | 8-K | Current Report |
Oct 16, 2024 | D | Filing |